Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Group A (current patients):
- Adults aged 18 or older who have lesions (abnormal growths) in the liver
- People with up to five liver tumors that cannot be surgically removed, where at least one of the following applies: the tumor is at least 3 cm in size; the tumor is located very close to large blood vessels; the tumor is located very close to sensitive nearby organs or structures (such as the bowel, stomach, diaphragm, or bile ducts); the tumor has a limited blood supply that makes certain standard treatments difficult to deliver; or the tumor has a large connection to blood flow leading to other vital organs
Group B (historical patients):
- People who would have met the Group A criteria above but did not receive a specific liver treatment (called HDRBT) between 1 January 2000 and 1 January 2021
Who may not be able to join:
- People who currently have an active infection or infectious disease
- People with serious uncontrolled health conditions, such as an active infection, lung disease, heart failure, unstable chest pain, irregular heartbeat, or mental health or personal circumstances that would make it difficult to follow the study requirements
- People whose cancer has spread widely throughout the body, unless the specific tumor being targeted is directly causing serious problems such as pain, blockages, or liver problems that are affecting quality of life (confirm with trial site)
- People who are pregnant; those who are sexually active must use birth control while taking part in the study
- People with advanced liver disease classified as Child-Pugh class C (a medical measure of liver function — confirm with trial site)
- People whose blood bilirubin level (a marker of liver function) is above 2 mg/dl
- People whose platelet count (cells that help blood clot) is below 50,000/ul
- People whose blood clotting test result (called INR) is above 1.5
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Joshua Kuban, M.D. Anderson Cancer Center
Phone: 713-745-0944
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To prospectively evaluate the clinical effectiveness of the use of high dose rate brachytherapy (HDRBT) for the treatment of both primary liver malignancies.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.